HOME ABOUT US SERVICES RESEARCH EQUITY DERIVATIVES IPO INTERNET TRADING FTP CONTACT US
  
SENSEX -449.23 -0.62%
71576.92
 
NIFTY -133.60 -0.62%
21577.20
 
Nasdaq 13.77 0.09%
14524.07
 
Nikkei 225 89.13 0.27%
33377.42
 
FTSE 100 -33.50 -0.43%
7689.60
 
YOU ARE ON
Equity
Equity Analysis
Price
Gainers & Losers
Out & Under Performers
Only Buyers & Sellers
Advances & Declines
New Highs & Lows
Weightage
5 Day's Up & Down
Historical Returns
Volume
Analysis
News Analysis
Corporate Action
Corporate Info
Other Market
 
Lincoln Pharmaceuticals Ltd.
 
Source DateBoard Meeting DateDetails
23-Oct-2023 02-Nov-2023 Quarterly Results
28-Jul-2023 10-Aug-2023 Quarterly Results
15-May-2023 25-May-2023 Dividend & Audited Results
31-Jan-2023 09-Feb-2023 Quarterly Results
31-Oct-2022 10-Nov-2022 Quarterly Results
28-Jul-2022 09-Aug-2022 Quarterly Results
11-May-2022 19-May-2022 Dividend
02-Feb-2022 10-Feb-2022 Quarterly Results
03-Nov-2021 11-Nov-2021 Quarterly Results
30-Sep-2021 05-Oct-2021 inter-alia to transact the following businesses: 1) To issue/ allot equity shares to the eligible shareholders of Lincoln Parenteral Ltd. pursuant to Scheme of Amalgamation of Lincoln Parenteral Limited ('Transferor Company') and Lincoln Pharmaceuticals Limited ('Transferee Company') and their respective shareholders and creditors, under Sections 230 to 232 and other applicable provisions of the Companies Act, 2013 as approved by the Hon'ble National Company Law Tribunal, Ahmedabad Bench vide its order dated September 14, 2021. 2) Any other item may be taken up for consideration with the permission of the Chairman and with the consent of a majority of the Directors present in the Meeting, if any.
30-Jul-2021 10-Aug-2021 Quarterly Results
17-May-2021 25-May-2021 LINCOLN PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 25/05/2021 ,inter alia, to consider and approve the audited standalone and consolidated financial results of the Company for the quarter and year ended on March 31, 2021 and recommendation of dividend on equity shares of the Company, if any, along with any other business, if any. Further, in continuation to our disclosure on closure of trading window dated March 31, 2021, pursuant to the provisions of the SEBI (Prohibition of Insider Trading) Regulations, 2015, trading window has been closed for trading in securities of the Company from April 01, 2021 and shall reopen after the expiry of 48 hours from the time the result becomes generally available.
25-Jan-2021 02-Feb-2021 Quarterly Results
26-Oct-2020 03-Nov-2020 Quarterly Results
13-Aug-2020 20-Aug-2020 Quarterly Results
15-Jun-2020 25-Jun-2020 Audited Results
24-Feb-2020 27-Feb-2020 Interim Dividend
06-Feb-2020 13-Feb-2020 Quarterly Results
03-Dec-2019 07-Dec-2019 Inter alia consider and approve the following: 1. To Withdrawal the In-principle application and Draft Scheme filed with NSE, earlier approved by the Board of Directors in its meeting held on September 19, 2019, on the ground that there is an error in considering relevant date according to SEBI Circular CFD/DIL3/CIR/2017/21 dated March 10, 2017. 2. To consider and approve draft scheme of amalgamation of Lincoln Parenteral Limited (?Transferor Company?) with Lincoln Pharmaceuticals Limited (?Transferee Company?), subject to necessary approvals. 3. Any other businesses with the permission of the Board.
04-Nov-2019 14-Nov-2019 Quarterly Results
Page 1 of 6
Prev || Next
 
ADINATH STOCK BROKING PVT LTD  :   SEBI REGISTRATION NUMBERS : Bombay Stock Exchange(BSE): CASH -INZ000204337 & DERIVATIVE -INZ000204337 Member ID-3175 National Stock Exchange(NSE): CASH- INZ000204337 & DERIVATIVES -INZ000204337 Member ID-12805 MCX-SX Stock Exchange(MCX-SX): Currency Derivative : INZ000204337 Member ID-44400 United Stock Exchange(USE): Currency Derivative: Central Depository Services Ltd(CDSL)- IN -DP-452/2008 DP ID 12055200
ADINATH COMMODITIES  :   COMMODITIES SEBI REGISTRATION NUMBERS : INZ000042629 MultiCommodity Exchange Ltd (MCX):Member ID -10140 National Commodity and Derivatives Exchange Ltd (NCDEX):Member ID -00622.
ATTENTION INVESTORS :   "Prevent unauthorised transactions in your Broking & demat account--> Update your mobile numbers/email IDs with your stock brokers & depository participate. Receive information of your transactions directly from Exchange & CDSL on your mobile/email at the end of the day......................Issued in the interest of Investors"
ATTENTION INVESTORS :   "KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary."
ATTENTION INVESTORS :   "No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account."
ATTENTION INVESTORS :   1. Stock Brokers can accept securities as margin from clients only by way of pledge in the depository system w.e.f. September 1, 2020. 2. Update your mobile number & email Id with your stock broker/depository participant and receive OTP directly from depository on your email id and/or mobile number to create pledge. 3. Pay 20% upfront margin of the transaction value to trade in cash market segment 4. Investors may please refer to the Exchange's Frequently Asked Questions (FAQs) issued vide circular reference NSE/INSP/45191 dated July 31, 2020 and NSE/INSP/45534 dated August 31, 2020 and other guidelines issued from time to time in this regard. 5. Check your Securities /MF/ Bonds in the consolidated account statement issued by NSDL/CDSL every month. "Issued in the interest of Investors"
| Disclaimer | Privacy Policy | Feedback | Terms and Conditions | Careers | Investor Grievances | Download | Investor Protection | SCORES | Site Map
Investor Charter - DP | Investor Charter - Stock Broker | e-voting | Investor Education
Useful links: NSE | BSE | MCX-SX | CDSL | SEBI | MCX | NCDEX | FMC | Smart ODR
SEBI Registration No.INZ000042629
Copyright © 2011 Adinath Stock Broking Pvt Ltd                             Designed, Developed & Content Powered By ●●● Accord Fintech Pvt.Ltd.